We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Tanya Dorff

Tanya B Dorff MD

Associate Clinical Professor; Head, GU Cancer Program, City of Hope, Duarte, California

Recent Contributions to PracticeUpdate:

  1. Defining Value in Metastatic Prostate Cancer
  2. Sequencing Atezolizumab and Sipuleucel-T for Castration-Resistant Prostate Cancer
  3. Bone Supportive Therapy and Radium-223 for Metastatic Prostate Cancer
  4. Chemotherapy for Oligometastatic Prostate Cancer
  5. Androgen Deprivation Therapy Plus Enzalutamide for Hormone-Sensitive Prostate Cancer
  6. Ipilimumab Plus Nivolumab for mCRPC
  7. Evidence-Based Chemotherapy for Oligometastatic Prostate Cancer
  8. Contemporary Management of Penile Cancer
  9. Potential Role for High Dose IL-2 in mRCC: New Data From ASCO GU 2018
  10. New Insights on Immune-Related Adverse Events in GU Cancers From ASCO GU 2018

Most Read This Week

Recently Updated